It's a great time to helm a large biotech company, generally. Big biotech players overall posted major growth last year, and their CEOs got richer in the process. Most got fat raises while others saw their bundles of pay pale in comparison to 2011 figures. We surveyed the total compensation packages of the 10 largest biotech companies based on market capitalization as of early May, sleuthing mostly proxy statements for the financial details on pay for some of the most powerful people in the industry. Check it out >>
Amgen's new CEO scored a big raise when he was promoted last year. Robert Bradway took over from ex-chief Kevin Sharer at the end of May, and by year's end, he had racked up $13.57 million in compensation for the year, almost twice what he made in 2011 as president and COO. And his predecessor's pay dropped by half, knocking him off our list of highest-paid biopharma executives.
The Thousand Oaks, CA-based biotech powerhouse made an unexpected move in December to buy the pioneering genomics company deCODE for $415 million. Today R&D chief Dr. Sean Harper further explained how the capabilities of the company fit within the broader strategy at Amgen to be more discerning about which research programs to pursue.
Amgen has been a constant surprise to investors this year, beating sales expectations last quarter and posting one of the biggest share run-ups of any of the major drug companies this year. But the biotech's new CEO did it again, with the company announcing a whopping 30% increase in its share dividend.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Biotech company Amgen says it will pay $415 million to buy Icelandic company deCODE Genetics, but the deal has some watchers wondering what Amgen's new CEO is really thinking here.
Two years after a pair of top biotech venture players brought struggling deCODE Genetics out of bankruptcy and reenergized its efforts to better understand the genetic triggers of disease, Amgen has swooped in to buy the Icelandic company for $415 million, spurring some head scratching over the match.
Some analysts say Bob Bradway will need to pull off more licensing and buyout deals if he wants to earn a good reputation for an up-an-coming pipeline effort.
Some analysts say that the new CEO at Amgen--Bob Bradway--will need to pull off licensing and buyout deals if he wants to earn a good reputation for an up-an-coming pipeline effort.
Amgen's ( $AMGN ) incoming CEO has high hopes for this year. Now COO, Robert Bradway says he's looking for revenue growth in 2012, thanks in part to international expansion. Another driver: Sales of